{
  "id": 758055,
  "title": "STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk",
  "url": "https://urgent.news/2026/08/13/stat-neurocrine-biosciences-and-the-delicate-balance-of-benefit-and",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-13T10:30:00.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/08/13/neurocrine-biosciences-vykat-prader-willi-2/"
  },
  "original_language": "en",
  "account": null,
  "summary": "When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. Such is the case with a therapy from Neurocrine Biosciences.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say",
        "url": "https://urgent.news/2026/08/12/stat-neurocrine-biosciences-rare-disease-drug-possibly-tied-to-safety",
        "published": "2026-08-12T08:30:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}